HOME

TheInfoList



OR:

Pruvanserin (EMD-281,014, LY-2,422,347) is a selective 5-HT2A receptor
antagonist An antagonist is a character in a story who is presented as the chief foe of the protagonist. Etymology The English word antagonist comes from the Greek ἀνταγωνιστής – ''antagonistēs'', "opponent, competitor, villain, enemy, riv ...
which was under development by
Eli Lilly and Company Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel ...
for the treatment of
insomnia Insomnia, also known as sleeplessness, is a sleep disorder in which people have trouble sleeping. They may have difficulty falling asleep, or staying asleep as long as desired. Insomnia is typically followed by daytime sleepiness, low energy, ...
. It was in
phase II Phase II, Phase 2 or Phase Two may refer to: Media * Marvel Cinematic Universe: Phase Two, six American superhero films from 2013–2015 * ''Star Trek: Phase II'', an unrealized television series based on the characters of Gene Roddenberry's ''S ...
clinical trial Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietar ...
s in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. In addition to its
sleep Sleep is a sedentary state of mind and body. It is characterized by altered consciousness, relatively inhibited sensory activity, reduced muscle activity and reduced interactions with surroundings. It is distinguished from wakefulness by a de ...
-improving properties, pruvanserin has also been shown to have
antidepressant Antidepressants are a class of medication used to treat major depressive disorder, anxiety disorders, chronic pain conditions, and to help manage addictions. Common side-effects of antidepressants include dry mouth, weight gain, dizziness, hea ...
, anxiolytic, and
working memory Working memory is a cognitive system with a limited capacity that can hold information temporarily. It is important for reasoning and the guidance of decision-making and behavior. Working memory is often used synonymously with short-term memory, ...
-enhancing effects in animal studies.


See also

*
Eplivanserin Eplivanserin (SR-46,349; planned trade name Ciltyri) was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis. Sanofi Aventis announced in December 2009 that it was withdrawing its application for approv ...
* Pimavanserin *
Glemanserin Glemanserin (International Nonproprietary Name, INN) (developmental code name MDL-11,939) is a drug which acts as a potency (pharmacology), potent and binding selectivity, selective 5-HT2A receptor, 5-HT2A receptor receptor antagonist, antagonist ...
*
Roluperidone Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for t ...
*
Volinanserin Volinanserin ( INN) (developmental code name MDL-100,907) is a highly selective 5-HT2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT2A receptor. It was also tested in clinical trials ...
*
Ziprasidone Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The IM form may be used for acute agitation ...
*
Lenperone Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class. It was first reported as an anti-emetic in 1974, and its use in treatment of acute schizophrenia was reported in 1975. Related early antipsychotic agents includ ...
*
Lidanserin Lidanserin (International Nonproprietary Name, INN; ZK-33,839) is a drug which acts as a combined 5-HT2A receptor, 5-HT2A and α1-adrenergic receptor, α1-adrenergic receptor receptor antagonist, antagonist. It was developed as an antihypertensiv ...


References

{{Serotonergics 5-HT2A antagonists Eli Lilly and Company brands Indoles Aromatic nitriles N-benzoylpiperazines Phenethylamines